However, we could not exclude the possibility that the reversal of ADA suppression may diminish the IL-13-induced increase in adenosine [14] and the possibility that this may be enhanced by simvastatin-inhibited IL-13 in our COPD patients. The gene discussed is IL13; the disease is chronic obstructive pulmonary disease.